B
NGNE icon

Bailard’s Neurogene NGNE Stock Holding History

Bailard’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,505
Closed -$93K – 725
2022
Q2 		$93K Buy
+4,505
New +$110K ﹤0.01% 655

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bailard's NGNE Position: Q3 2022 in Review

Bailard sold out of Neurogene (NGNE) in Q3 2022, closing a stake of 4,505 shares — an estimated $93K sold.

Bailard first reported a position in NGNE in Q2 2022 and held it in 1 quarter. The position peaked at $93K in Q2 2022. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

  • Bailard reported no remaining Neurogene position as of Q3 2022 after selling out during the quarter.
  • Bailard sold 4,505 Neurogene shares in Q3 2022, an estimated $93K.
  • Bailard first reported a position in Neurogene in Q2 2022 and held it in 1 quarter.
  • Bailard's Neurogene position peaked at $93K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.